Afficher la notice abrégée

3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort

dc.rights.licenseopenen_US
dc.contributor.authorGODIN, O.
dc.contributor.authorPIGNON, B.
dc.contributor.authorSZOKE, A.
dc.contributor.authorBOYER, L.
hal.structure.identifierNutrition et Neurobiologie intégrée [NutriNeuro]
dc.contributor.authorAOUIZERATE, Bruno
IDREF: 069471851
dc.contributor.authorSCHORR, B.
dc.contributor.authorANDRÉ, M.
dc.contributor.authorCAPDEVIELLE, D.
dc.contributor.authorCHEREAU, I.
dc.contributor.authorCOULON, N.
dc.contributor.authorDASSING, R.
dc.contributor.authorDUBERTRET, C.
dc.contributor.authorETAIN, B.
dc.contributor.authorLEIGNIER, S.
dc.contributor.authorLLORCA, P. M.
dc.contributor.authorMALLET, J.
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorMISDRAHI, David
dc.contributor.authorPASSERIEUX, C.
dc.contributor.authorREY, R.
dc.contributor.authorURBACH, M.
dc.contributor.authorSCHÜRHOFF, F.
dc.contributor.authorLEBOYER, M.
dc.contributor.authorFOND, G.
dc.date.accessioned2023-05-31T14:42:49Z
dc.date.available2023-05-31T14:42:49Z
dc.date.issued2023-01-10
dc.identifier.issn0278-5846en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182396
dc.description.abstractEnAims Metabolic Syndrome (MetS) is a major health epidemic of Western countries and patients with schizophrenia is a particularly vulnerable population due to lifestyle, mental illness and treatment factors. However, we lack prospective data to guide prevention. The aim of our study is then to determine MetS incidence and predictors in schizophrenia. Method Participants were recruited in 10 expert centers at a national level and followed-up for 3 years. MetS was defined according to the International Diabetes Federation criteria. Inverse probability weighting methods were used to correct for attrition bias. Results Among the 512 participants followed-up for 3 years, 77.9% had at least one metabolic disturbance. 27.5% were identified with MetS at baseline and excluded from the analyses. Among the rest of participants (N = 371, mean aged 31.2 (SD = 9.1) years, with mean illness duration of 10.0 (SD = 7.6) years and 273 (73.6%) men), MetS incidence was 20.8% at 3 years and raised to 23.6% in tobacco smokers, 29.4% in participants receiving antidepressant prescription at baseline and 42.0% for those with 2 disturbed metabolic disturbances at baseline. Our multivariate analyses confirmed tobacco smoking and antidepressant consumption as independent predictors of MetS onset (adjusted odds ratios (aOR) = 3.82 [1.27–11.45], p = 0.016, and aOR = 3.50 [1.26–9.70], p = 0.0158). Antidepressant prescription predicted more specifically increased lipid disturbances and paroxetine was associated with the highest risk of MetS onset. Conclusion These results are an alarm call to prioritize MetS prevention and research in schizophrenia. We have listed interventions that should be actively promoted in clinical practice.
dc.description.sponsorshipSorbonne Universités à Paris pour l'Enseignement et la Rechercheen_US
dc.description.sponsorshipFondaMental-Cohortes - ANR-10-COHO-0010en_US
dc.language.isoENen_US
dc.subject.enDepression
dc.subject.enDepressive disorders
dc.subject.enMental health
dc.subject.enMetabolic syndrome
dc.subject.enPsychiatry
dc.subject.enschizophrenia
dc.title.en3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort
dc.title.alternativeProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.pnpbp.2022.110641en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed36122839en_US
bordeaux.journalProgress in Neuro-Psychopharmacology and Biological Psychiatryen_US
bordeaux.page110641en_US
bordeaux.volume120en_US
bordeaux.hal.laboratoriesNutriNeuro (Laboratoire de Nutrition et Neurobiologie Intégrée) - UMR 1286en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINRAEen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Progress%20in%20Neuro-Psychopharmacology%20and%20Biological%20Psychiatry&rft.date=2023-01-10&rft.volume=120&rft.spage=110641&rft.epage=110641&rft.eissn=0278-5846&rft.issn=0278-5846&rft.au=GODIN,%20O.&PIGNON,%20B.&SZOKE,%20A.&BOYER,%20L.&AOUIZERATE,%20Bruno&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée